Why is Valneva stock falling today?

Valneva SE (VALN) shares dropped after the UK revoked approval for its Ixchiq chikungunya vaccine. The decision, based on a benefit-risk assessment, does not affect Ixchiq's licenses in other territories. Valneva expects minimal financial impact and will not appeal. The company cites positive safety data from other regions.

Valneva SE (VALN) shares fell ~5% after the UK revoked the marketing authorization for its chikungunya vaccine, Ixchiq, due to safety concerns, according to the company. The vaccine was launched in 2023 and is the first of its kind. The move impacts Valneva's revenue and market position in the vaccine sector.

Valneva's stock (VALN) fell 7% after hours as the UK revoked authorization for its IXCHIQ vaccine. The company had previously cut its 2026 sales outlook to €135M-€150M, citing weak demand. VALN stock is down 33% year-to-date, with neutral retail sentiment.

Valneva SE ADR stock fell 5.9% to $5.53 after the UK revoked its chikungunya vaccine's marketing authorization. The company stated the financial impact is limited and no recall costs are expected. The European Medicines Agency and Health Canada maintained the vaccine's authorizations. The stock is trading near its 52-week low of $4.75.

Valneva SE ADRs (VALN) dropped 6.5% after the UK revoked IXCHIQ's marketing authorization due to a benefit-risk review. The MHRA's decision was based on existing safety data, not new signals. The revocation does not affect IXCHIQ's licenses in other regions. Valneva expects minimal financial impact and will not appeal, focusing on endemic territories. Approximately 187,000 doses have been administered globally.

Valneva SE (VALN) announced the UK revoked marketing authorization for its chikungunya vaccine, IXCHIQ, after a safety review. The decision, not tied to new safety concerns, does not affect IXCHIQ's approval in other regions. Valneva stated minimal financial impact and no plans to appeal, focusing on markets with higher chikungunya risk.